Pi-88 merely manages the symptoms, whereas there are multiple drugs being trialled that solve the problems at source. The drug, even if it gets to market, will have a shelf life of 6 months at best.
The market is starting to recognise this, and a re-rating is in progress. This wave of selling is just the beginning.
